May 28, 2018 12:04 AM ET

Healthcare Equipment and Supplies

Company Overview of Vasorum Ltd.

Company Overview

Vasorum Ltd. develops medical devices for diagnostic and interventional cardiology and radiology markets. It offers Celt ACD, an arterial puncture closure device that affects the closure of a puncture site after percutaneous catheter-based vascular procedures, such as angiography, angioplasty, and placement of a stent. The company markets its products in Ireland and the United States. Vasorum Ltd. was incorporated in 2005 and is based in Dublin, Ireland.

Trinitas House

2012 Orchard Avenue

Citywest Business Campus

Dublin,  D24 WPW6

Ireland

Founded in 2005

Phone:

353 1 403 5460

Fax:

353 1 403 5488

Key Executives for Vasorum Ltd.

Co-Founder, Chairman of the Board and Chief Executive Officer
Co-Founder and Director of Research & Development
Co-Founder and Director of Business Development
Compensation as of Fiscal Year 2017.

Vasorum Ltd. Key Developments

Vasorum Ltd. Launches Celt ACD® Second Generation Vascular Closure Device in the USA

Vasorum Ltd., following FDA approval of its PMA supplement, the developer and manufacturer of the novel Celt ACD® vascular closure device has added a 7F sized Celt ACD® device to its Celt ACD® 6F and Celt ACD® 5F size range in the USA. Celt ACD® is indicated for arterial puncture closure in both diagnostic and interventional cardiology and radiology patients. Celt ACD® offers excellent time to hemostasis in a wide variety of clinical situations. The second generation Celt ACD® devices now available in both the USA and Europe have a new improved delivery system which has been designed to enhance the user experience during deployment.

Vasorum Ltd Receives FDA Approval for Celt ACD® Vascular Closure Device

Vasorum Ltd. announced that Celt ACD vascular closure device has received approval of its PMA application from the US Food and Drug Administration (FDA). Celt ACD®, which previously received CE mark and is sold in Europe, is indicated for arterial puncture closure in both diagnostic and anticoagulated percutaneous interventional cardiology and radiology patients. Celt ACD® offers excellent time to hemostasis in a wide variety of clinical situations. A randomized controlled clinical trial which recruited 207 interventional cardiology procedure patients was carried out in four International Cardiology Centres across US and Europe.

Similar Private Companies By Industry

Company Name Region
Advanced Surgical Concepts Limited Europe
Aegis Surgical Limited Europe
Aerogen Limited Europe
AeroSurgical Ltd. Europe
AltaScience Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vasorum Ltd., please visit vasorum.ie. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.